Having trouble accessing articles? Reset your cache.

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase

Read the full 347 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers